Clinical Trial

Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC

Name: Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC — clinical trial record (NCT07244874)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

This study is aimed to evaluate the efficacy and safety of Sacituzumab Tirumotecan combined with Toripalimab for first-line treatment of PD-L1 positive unresectable Locally Advanced/metastatic triple negative breast cancer (a/mTNBC).

Trial Details

NCT Number	NCT07244874
Lead Sponsor	Tianjin Medical University Cancer Institute and Hospital Collaborators: Southwest Hospital, China
Conditions	TNBC - Triple-Negative Breast Cancer, PD-L1 Positive
Enrollment	41 participants
Start Date	2025-12-01
Primary Completion	2028-01-30 (estimated)
Study Completion	2029-07-30 (estimated)
Updated on ClinicalTrials.gov	2025-11-24